Lipid-based Nanoparticles for Drug Delivery in Parkinson's Disease

Overview

Journal Transl Neurosci

Specialty Neurology

Date 2024 Dec 10

PMID 39654878

Authors

Han Cai

Dong Liu

Wei-Wei Xue

Liya Ma

Hai-Tao Xie

Ke Ning

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder that predominantly affects dopaminergic neurons in the substantia nigra and ventral tegmental area, resulting in symptoms such as tremors, muscle rigidity, bradykinesia, and potential cognitive and affective disturbances. The effective delivery of pharmacological agents to the central nervous system is hindered by various factors, including the restrictive properties of the blood‒brain barrier and blood‒spinal cord barrier, as well as the physicochemical characteristics of the drugs. Traditional drug delivery methods may not provide the therapeutic concentrations necessary for functional restoration in PD patients. However, lipid-based nanoparticles (NPs) offer new possibilities for enhancing the bioavailability of established treatment regimens and developing innovative therapies that can modify the course of the disease. This review provides a concise overview of recent advances in lipid-based NP strategies aimed at mitigating specific pathological mechanisms relevant to PD progression. This study also explores the potential applications of nanotechnological innovations in the development of advanced treatment modalities for individuals with PD.

References

Setten R, Rossi J, Han S . The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019; 18(6):421-446. DOI: 10.1038/s41573-019-0017-4. View

Kulkarni J, Witzigmann D, Leung J, Tam Y, Cullis P . On the role of helper lipids in lipid nanoparticle formulations of siRNA. Nanoscale. 2019; 11(45):21733-21739. DOI: 10.1039/c9nr09347h. View

Uppuluri C, Ravi P, Dalvi A . Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. Int J Pharm. 2021; 606:120881. DOI: 10.1016/j.ijpharm.2021.120881. View

Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

Beloqui A, Solinis M, Rodriguez-Gascon A, Almeida A, Preat V . Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine. 2015; 12(1):143-61. DOI: 10.1016/j.nano.2015.09.004. View

Zhang Z, Li Y, Liu X, Huang F, Liu T, Jiang D . Human umbilical cord blood stem cells and brain-derived neurotrophic factor for optic nerve injury: a biomechanical evaluation. Neural Regen Res. 2015; 10(7):1134-8. PMC: 4541247. DOI: 10.4103/1673-5374.160110. View

Ngwuluka N, Pillay V, Choonara Y, Modi G, Naidoo D, du Toit L . Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery. Int J Mol Sci. 2011; 12(9):6194-225. PMC: 3189777. DOI: 10.3390/ijms12096194. View

Abeliovich A, Gitler A . Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature. 2016; 539(7628):207-216. DOI: 10.1038/nature20414. View

Cortesi R, Esposito E, Drechsler M, Pavoni G, Cacciatore I, Sguizzato M . L-dopa co-drugs in nanostructured lipid carriers: A comparative study. Mater Sci Eng C Mater Biol Appl. 2016; 72:168-176. DOI: 10.1016/j.msec.2016.11.060. View

10.

Shalaby K, El-Agnaf O . Gene-Based Therapeutics for Parkinson's Disease. Biomedicines. 2022; 10(8). PMC: 9331241. DOI: 10.3390/biomedicines10081790. View

11.

Wang Y, Xu H, Fu Q, Ma R, Xiang J . Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J Neurol Sci. 2011; 304(1-2):29-34. DOI: 10.1016/j.jns.2011.02.025. View

12.

Pardeshi C, Belgamwar V, Tekade A, Surana S . Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 2013; 24(9):2101-15. DOI: 10.1007/s10856-013-4965-7. View

13.

Gohla S, Dingler A . Scaling up feasibility of the production of solid lipid nanoparticles (SLN). Pharmazie. 2001; 56(1):61-3. View

14.

Li Y, Chen Z, Lu Z, Yang Q, Liu L, Jiang Z . "Cell-addictive" dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway. Theranostics. 2018; 8(19):5469-5481. PMC: 6276100. DOI: 10.7150/thno.28295. View

15.

Fields C, Bengoa-Vergniory N, Wade-Martins R . Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci. 2019; 12:299. PMC: 6906193. DOI: 10.3389/fnmol.2019.00299. View

16.

Lee G, Dallas S, Hong M, Bendayan R . Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev. 2001; 53(4):569-96. View

17.

Cano A, Espina M, Garcia M . Recent Advances on Antitumor Agents-loaded Polymeric and Lipid-based Nanocarriers for the Treatment of Brain Cancer. Curr Pharm Des. 2020; 26(12):1316-1330. DOI: 10.2174/1381612826666200116142922. View

18.

Xiang Y, Wu Q, Liang L, Wang X, Wang J, Zhang X . Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model. J Drug Target. 2011; 20(1):67-75. DOI: 10.3109/1061186X.2011.595490. View

19.

Simon D, Tanner C, Brundin P . Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2019; 36(1):1-12. PMC: 6905381. DOI: 10.1016/j.cger.2019.08.002. View

20.

Liu K, Wen C, Yen T, Sung K, Ku M, Wang J . Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting. Nanotechnology. 2012; 23(9):095103. DOI: 10.1088/0957-4484/23/9/095103. View